A Phase I Dose-Escalation Clinical Trial of Bronchoscopic Cryoimmunotherapy in Advanced-Stage NSCLC

Introduction: Outcomes for NSCLC remain suboptimal. Recent data suggest that cryoablation can generate antitumor immune effects. In this first-in-human phase I clinical trial, we investigated the safety and feasibility of bronchoscopic cryoimmunotherapy (BCI) delivered during standard-of-care bronch...

Descrición completa

Detalles Bibliográficos

Principais autores:	Jun-Chieh J. Tsay, MD, MS, Antonio Velez, MD, Destiny Collazo, BS, Isaac Laniado, MD, Jamie Bessich, MD, Vivek Murthy, MD, Andrew DeMaio, MD, Samaan Rafeq, MD, Benjamin Kwok, MD, Fares Darawshy, MD, Ray Pillai, MD, Kendrew Wong, MD, Yonghua Li, MD, PhD, Rosemary Schluger, RN, Alena Lukovnikova, BS, Sofia Roldan, BS, Matt Blaisdell, BS, Fernanda Paz, Kelsey Krolikowski, BS, Katherine Gershner, MD, Yong Liu, PhD, Judy Gong, BA, Sara Borghi, PhD, Fang Zhou, MD, Aristotelis Tsirigos, PhD, Harvey Pass, MD, Leopoldo N. Segal, MD, MS, Daniel H. Sterman, MD
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2025-08-01
Series:	JTO Clinical and Research Reports
Assuntos:	Bronchoscopic cryoimmunotherapy Immunotherapy Tumor microenvironment NSCLC Phase I trial
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2666364325000669
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!